iSTEP-N
Opioid Use Disorder (OUD)
Key Facts
About Akyso Therapeutics
Akyso Therapeutics is a clinical-stage biotech advancing the iSTEP platform, a tunable, bioabsorbable polymeric implant for ultra-long-acting drug delivery. Its lead program, iSTEP-N (naltrexone), has completed a Phase 1a trial, with a Phase 1b PK study slated for Q1 2026, targeting the significant compliance challenges in opioid use disorder treatment. The pipeline also includes a buprenorphine implant for OUD and exploratory work on a GLP-1 agonist implant for weight loss, positioning the company at the intersection of advanced drug delivery and high-need therapeutic areas. As a private, pre-revenue company, Akyso is seeking to translate its versatile technology into novel treatments that improve patient adherence and outcomes.
View full company profileAbout Akyso Therapeutics
Akyso Therapeutics is a clinical-stage biotech advancing the iSTEP platform, a tunable, bioabsorbable polymeric implant for ultra-long-acting drug delivery. Its lead program, iSTEP-N (naltrexone), has completed a Phase 1a trial, with a Phase 1b PK study slated for Q1 2026, targeting the significant compliance challenges in opioid use disorder treatment. The pipeline also includes a buprenorphine implant for OUD and exploratory work on a GLP-1 agonist implant for weight loss, positioning the company at the intersection of advanced drug delivery and high-need therapeutic areas. As a private, pre-revenue company, Akyso is seeking to translate its versatile technology into novel treatments that improve patient adherence and outcomes.
View full company profileTherapeutic Areas
Other Opioid Use Disorder (OUD) Drugs
| Drug | Company | Phase |
|---|---|---|
| INV-202 (Buprenorphine LAIN) | Indivior | Phase 3 |
| iSTEP-B | Akyso Therapeutics | Pre-clinical |
| BT-219 | Bridge Therapeutics | Pre-clinical |